Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 34: 2026-2030, 1988;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kropf, J.
Right arrow Articles by Negwer, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kropf, J.
Right arrow Articles by Negwer, A.

Clinical Chemistry, Vol 34, 2026-2030, Copyright © 1988 by American Association for Clinical Chemistry

Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases

J Kropf, AM Gressner and A Negwer
Abteilung fur Klinische Chemie, Klinikum der Philipps Universitat, Marburg, F.R.G.

We examined the efficacy of laminin assay in serum for diagnosis of fibrotic liver diseases. Values for subjects with liver disease significantly (P less than 0.05) exceeded those for healthy subjects and patients with nonhepatic diseases. At a cutoff value of 1.45 kilo- units(arb.)/L (approximately 330 micrograms/L) and an assumed prevalence of fibrotic liver diseases of 0.5, positive and negative predictive values of the test were 0.97 and 0.83, respectively, for the comparison with a healthy reference population and 0.81 and 0.80 for nonhepatic diseased patients. Increases in laminin concentration were positively correlated with the extent of fibrotic transition of the liver. Discrimination between fibrotic and cirrhotic stages of chronic liver diseases by means of laminin assay was better than with the amino- terminal propeptide of type III procollagen. According to the criteria of diagnostic efficacy, we conclude that determination of laminin in serum improves the possibilities of clinical-chemical diagnosis of liver fibrosis and cirrhosis. However, as commonly true for other biochemical tests, determination of laminin cannot replace conventional diagnostic methods.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
D. R. Dufour, J. A. Lott, F. S. Nolte, D. R. Gretch, R. S. Koff, and L. B. Seeff
Diagnosis and Monitoring of Hepatic Injury. II. Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Monitoring
Clin. Chem., December 1, 2000; 46(12): 2050 - 2068.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American Association for Clinical Chemistry.